Solta Medical Inc

Solta Medical — Thermage — Merger or Acquisition (August 2008)

42 slides from Solta Medical's merger presentation, Aug 14, 2008

  1. Slide 1: Thermage, Inc.

    Thermage, Inc. Thermage, Inc. (Nasdaq: THRM) (Nasdaq: THRM) Stephen Fanning Stephen Fanning Chairman and CEO Chairman and CEO Filed by Thermage, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Thermage,

  2. Slide 2: Additional Information and Where You Can Find It

    Additional Information and Where You Can Find It This communication may be deemed to be solicitation material in respect of the proposed transaction between Thermage and Reliant. In connection with the transaction, Thermage filed a registration statement on Form S-4 with the SEC containing a proxy s

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding potential transaction timing, projected financial results, and anticipated cost

  4. Slide 4: Creating a Global Leader

    Creating a Global Leader Creating a Global Leader • Combines the leaders in two of the largest segments of the aesthetic device industry – skin tightening and skin resurfacing • Strong economies of scale and substantial cost synergies • Creates one of the largest sales forces in aesthetic devices wi

  5. Slide 5: Aesthetic Market Overview

    Aesthetic Market Overview Aesthetic Market Overview Key Growth Drivers Key Growth Drivers • Aging of U.S. Population • Broader Range of Non-invasive Treatments • Changing Practitioner Economics – managed care and government reimbursement restrictions • Increased Acceptance of Aesthetic Procedures En

  6. Slide 6: Aesthetic Market Overview: Strong U.S. Non-surgical Growth

    Aesthetic Market Overview Aesthetic Market Overview Strong U.S. Non-surgical Growth Strong U.S. Non-surgical Growth • U.S. procedures increased 105% from 2000 to 2007 • Non-surgical procedures are driving the trend (+123%) 1.4 2.1 0.0 0.5 1.0 1.5 2.0 2.5 4.3 9.6 0.0 2.0 4.0 6.0 8.0 10.0 12.0 Surgica

  7. Slide 7: Market Size

    Market Size Market Size U.S. Practitioners Core Market Over 11,000 Dermatologists & 7,000 Plastic Surgeons Non-Core Market 133,000 physicians in other specialties Over 1,300 systems have been installed in the U.S. 67% to Core Physicians & 33% to Non-Core Physicians

  8. Slide 8: Thermage: Reshaping Your Future

    —_ \ Thermage’ Reshaping Your Future

  9. Slide 9: Thermage Solution

    Thermage Solution Thermage Solution • Non-invasive, Non-ablative Alternative to Surgery • Single Procedure Treatment • Controlled Heating of Collagen through Clinically- Proven Technology • Compelling Physician Economics

  10. Slide 10: Capacitive Coupling

    Capacitive Coupling Treatment Tip 1 Thermistor (Temperature Sensor) at each corner of treatment tip surface (total of 4) Internal EPROM Programmable Memory Chip Tip-to-Skin Detection: Prevents RF delivery if all four corners are not in contact with the skin Single-Patient-Use ThermaTip ThermaTip ~ 9

  11. Slide 11: Dominant Proprietary IP

    Dominant Proprietary IP Dominant Proprietary IP • 114 Patents Filed Worldwide – 32 Issued in the U.S., 21 Issued Overseas, 62 pending • Validated by Competition – Syneron, Inc. > Paid license settlement in 2005 > Admitted patents are valid > Thermage licensed bi-polar conductive RF to Syneron

  12. Slide 12: Demonstrated Efficacy and Safety

    Demonstrated Efficacy and Safety Demonstrated Efficacy and Safety Robust FDA 510k Clearances: • Periorbital - November 2002 • Face - June 2004 • Full body - December 2005 • Cellulite - October 2006 • Upper & Lower Eyelids – June 2007 > First & Only Non-invasive Device Indication for Eyelids < Over F

  13. Slide 13: Quotes from Scientific Journals

    Quotes from Scientific Journals Quotes from Scientific Journals “94% were satisfied with the treatment and only 5% felt the treatment was too painful “ Survey of 5,700 patient treatments Dr. Jeffrey Dover & Dr. Brian Zelickson, American Society for Dermatologic Surgery , August 2007) "Our data… indi

  14. Slide 14: Current Applications

    Current Applications Current Applications Body by Thermage Tighten, contour and rejuvenate skin anywhere on the body Face by Thermage: Full face and neck Eyes by Thermage: Eyelids and periorbital area Hands by Thermage: Top surface of hands (Q1 ‘07) Lips by Thermage: Fuller, smoother, more defined l

  15. Slide 15: Face by Thermage

    Face by Thermage Face by Thermage Pre-Treatment 2 Months Post Treatment

  16. Slide 16: Eyes by Thermage

    Eyes by Thermage Eyes by Thermage Pre-Treatment 2 Months Post Treatment

  17. Slide 17: Tummy by Thermage

    Tummy by Thermage Tummy by Thermage Pre-Treatment Three Months Post Treatment

  18. Slide 18: Cellulite Procedure by Thermage

    Cellulite Procedure by Thermage Cellulite Procedure by Thermage

  19. Slide 19: Revenue Streams

    Revenue Streams Revenue Streams Key Products ThermaCool NXT(59%), System Upgrades (26%) The ThermaCool System RF Generators Incl. New & Upgrades Other consumables: return pads, coupling fluid, cryogen, grid paper Extended service contracts Other Consumables & Service Gross Margin ~45% ~90% 0.25, 1.0

  20. Slide 20: Thermage 2nd Quarter Overview

    3 Months Ended June 30, ($ in thousands, except per share data) 2008 2007 Thermage 2nd Quarter Overview Thermage 2nd Quarter Overview • Sales of tips & consumables were up 15% from Q2 2007 • Gross profit margin of 77.1% vs. 72.5% prior year • Operating expenses held in check despite expansion of U.S

  21. Slide 21: Fraxel

    fraxel .%e

  22. Slide 22: The Gold Standard in Skin Resurfacing & Skin Rejuvenation

    • Pioneer of fractional technology • One of the most recognized and fastest growing brands in aesthetics • Large installed base of over 1,700 • Growing consumable revenue stream from tip sales leading to increased margins • A track record of innovation and a strong product pipeline • Broad patent pr

  23. Slide 23: Reliant Product Overview

    Fraxel re:pair Fraxel re:fine Fraxel re:store Reliant Product Overview Reliant Product Overview $79,000 $119,000 $129,000 System – List Price $400 $400 $400 Treatment Tip – List Price 5-6 full face treatments 3-5 full face treatments 1 full face treatment Approximate tip life Yes 1-2 Ablative Januar

  24. Slide 24: Superior Fractional Technology

    Superior Fractional Technology Superior Fractional Technology • Continuous motion scanning technology • Faster treatments • More uniform treatments • More effective results • Simpler, safer treatments • Greater reliability at total lower cost of ownership • Wide range in depth of treatment

  25. Slide 25: Fraxel Results

    Fraxel Fraxel Results Results Before After

  26. Slide 26: Fraxel Results

    Fraxel Fraxel Results Results

  27. Slide 27: Fraxel Results

    Fraxel Fraxel Results Results Before After

  28. Slide 28: Fraxel Results

    Fraxel Fraxel Results Results

  29. Slide 29: Reliant Has Been One of the Highest Growth Aesthetics Companies

    Reliant Has Been One of the Highest Growth Aesthetics Companies An Industry Leader in Revenue Growth An Industry Leader in Revenue Growth 23% 12% 19% 11% 1% 1% 19% 11% 10% 0% 5% 10% 15% 20% 25% Q1 '08 Q2 '08 Reliant Index NewCo Note: Growth shown as compared to the quarter of the previous year Index

  30. Slide 30: Systems and Consumables Driving Revenue Growth at Reliant

    Income Statement Year Ending 3 Months Ending ($ in millions) 12/31/2007 3/31/2008 6/30/2008 Systems and Consumables Driving Systems and Consumables Driving Revenue Growth at Reliant Revenue Growth at Reliant Fraxel’s Continued Strong Growth Prospects • Continued momentum for re:pair • Pending foreig

  31. Slide 31: Reliant Achieves Break-Even Non-GAAP Operating Income

    Income Statement Year Ending 3 Months Ending 3 Months Ending ($ in millions) 12/31/07 % of Rev 3/31/08 % of Rev 6/30/08 % of Rev Comments Reliant Achieves Break-Even Non- Reliant Achieves Break-Even Non- GAAP Operating Income* GAAP Operating Income* *Non-GAAP Operating Income excludes SBC and extrao

  32. Slide 32: Thermage Fraxel: Reshaping Your Future

    oN "os Thermage _fraxel ,.®e Reshaping Your Future *@.°

  33. Slide 33: Combining Two Highly Complementary Business Models

    Combining Two Highly Combining Two Highly Complementary Business Models Complementary Business Models Revenue Streams for the 6 Months Ending June 30, 2008 72% 26% 2% 23% 72% 5% 45% 51% 4% 0% 20% 40% 60% 80% 100% Thermage Reliant NewCo Tips Systems Other

  34. Slide 34: Enhanced Opportunity to Grow Consumable Revenue Stream

    Thermage $24.6mm Thermage >2,500 Enhanced Opportunity to Grow Enhanced Opportunity to Grow Consumable Revenue Stream Consumable Revenue Stream Treatment Tips and Consumables Revenue 6 Months Ending June 30, 2008 • Dedicated consumables sales force markets to Reliant’s installed base • Proven coopera

  35. Slide 35: Creating One of the Largest Sales Forces in Aesthetic Devices

    Largest Bifurcated U.S. Sales Force Focus on Disposables Focus on Generators Enhances Market Penetration Creating One of the Largest Sales Creating One of the Largest Sales Forces in Aesthetic Devices Forces in Aesthetic Devices

  36. Slide 36: Slide 36

  37. Slide 37: Slide 37

  38. Slide 38: Slide 38

  39. Slide 39: Substantial Synergies Identified

    Substantial Synergies Identified Substantial Synergies Identified Headcount Related – 66 positions • Sales $2.2mm • Marketing $2.3mm • Operations $1.4mm • G&A $3.4mm TOTAL HEADCOUNT $9.3mm Other Costs • Marketing $2.0mm • Facilities $0.5mm • R&D $1.0mm • Consulting, Legal, Insurance, Audit $1.2mm TO

  40. Slide 40: Benefit From Economies of Scale

    70% 68% 66% 62% 50% 56% 56% 0% 20% 40% 60% 80% CYNO CLZR ELOS Post- Merger CUTR PMTI THRM Reliant Benefit From Economies of Scale Benefit From Economies of Scale Q2 ’08 Operating Expenses as a % of Revenue Avg. of 54% Avg. of 67% $39 Q2 ’08 Revenue ($ in millions) $40 $38 $40 $25 $23 $18 $23 CLZR an

  41. Slide 41: Projected Liquidity of Combined Company

    Cash $52.2mm $25mm Cash Paid to Reliant at Close $5mm Cash Lent to Reliant $8mm Transacti on/One- Time Expenses Cash ~$16mm Estimated Cash Flow from Operations ~$15mm Projected Liquidity of Combined Company Projected Liquidity of Combined Company $0 $1mm Repayment of Assumed Debt and Interest 6/30/0

  42. Slide 42: Summary

    Summary Summary • Combines the leaders in two of the largest segments of the aesthetic device industry – skin tightening and skin resurfacing • Strong economies of scale and substantial cost synergies • Creates one of the largest sales forces in aesthetic devices with significant cross-selling oppor

Thermage — Merger or Acquisition (August 2008) on 6ix